重庆吉斯瑞

Chongqing Jisirui Biopharmaceutical is a Chinese biotechnology company focused on the discovery and development of innovative small molecule therapeutics for metabolic and endocrine disorders. The company specializes in multi-agonist treatments targeting the GLP-1, GIP, and Glucagon receptors to address unmet needs in obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). By leveraging its expertise in medicinal chemistry, Jisirui aims to develop oral alternatives to existing injectable peptide therapies. The company is currently advancing several candidates through the pre-clinical stage with the goal of entering human clinical trials.